Westchester Capital Management (New York)’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Westchester Capital Management (New York)’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-90,638	Closed	-$5.32M	–	306
2023 Q4	$5.32M	Buy	+90,638	New	+$5.1M	0.19%	80

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Westchester Capital Management (New York)'s MRTX Position: Q1 2024 in Review

Westchester Capital Management (New York) sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 90,638 shares — an estimated $5.32M sold.

Westchester Capital Management (New York) first reported a position in MRTX in Q4 2023 and held it in 1 quarter. The position peaked at $5.32M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Westchester Capital Management (New York) reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Westchester Capital Management (New York) sold 90,638 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $5.32M.
Westchester Capital Management (New York) first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
Westchester Capital Management (New York)'s Mirati Therapeutics, Inc. Common Stock position peaked at $5.32M in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Westchester Capital Management (New York)'s 13F filing for Q1 2024, filed 15 May 2024.